

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



**Austar Lifesciences Limited**

**奧星生命科技有限公司**

*(Incorporated in the Cayman Islands with limited liability)*

**(Stock Code: 6118)**

## **PROFIT WARNING**

This announcement is made by Austar Lifesciences Limited (“**Company**” and together with its subsidiaries, the “**Group**”) pursuant to Rule 13.09 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (“**Listing Rules**”) and the Inside Information Provisions (as defined in the Listing Rules).

The board (“**Board**”) of directors (“**Directors**”, each a “**Director**”) of the Company wishes to inform the shareholders of the Company and potential investors that, based on information currently available, the Group is expected to record a substantial increase in loss attributable to the shareholders of the Company for the six months ending 30 June 2017 as compared to a loss attributable to the shareholders of the Company of approximately RMB12.1 million for the corresponding period in 2016. Such loss is mainly attributable to (i) an increase in budgeted costs mainly due to prolonged execution time for certain projects undertaken by the Group resulting in decrease in gross profit of the Group; (ii) substantial decrease in revenue from the liquid and bioprocess segment which is the major revenue contributor of the Group as compared with the corresponding period in 2016; and (iii) certain projects with lower gross profit margin were executed during the period in an attempt to secure orders for increasing the market share of the bioprocess market as well as retaining long term customers. Nonetheless, the effect of such decrease is partially offset by a substantial increase in revenue from the life science consumables segment of the Group.

As the period covered by the six months ending 30 June 2017 has not yet ended, the information contained in this announcement is only based on the preliminary assessment by the management of the Company by information currently available to the Group including the unaudited consolidated management accounts of the Group for five months ended 31 May 2017 and is not based on any figure or information which has been audited or reviewed by the Company’s auditors and may be subject to change. Details of the Group’s financial information and performance will be disclosed when the Group’s interim results for the six months ending 30 June 2017 are announced.

**Shareholders of the Company and potential investors should exercise caution when dealing in the shares of the Company.**

On behalf of the Board  
**Austar Lifesciences Limited**  
**Ho Kwok Keung, Mars**  
*Chairman and Chief Executive Officer*

Hong Kong, 13 June 2017

*As at the date of this announcement, the Board comprises four executive Directors, namely Mr. Ho Kwok Keung, Mars, Mr. Ho Kin Hung, Mr. Chen Yuewu and Madam Zhou Ning; one non-executive Director, namely Madam Ji Lingling; and three independent non-executive Directors, namely Mr. Cheung Lap Kei, Madam Chiu Hoi Shan and Mr. Raco Ivan Jordanov (alias Racho Jordanov).*